BioTrinity 2026
April 14-15, 2026
Convene, 133 Houndsditch, London EC3A 7BX, United Kingdom
Medicilon and Hailu Biotech of Yangtze River Pharmaceutical Group Forge Strategic Cooperation to Accelerate New Drug R&D and Global Outreach
On March 30, Medicilon held a strategic cooperation signing ceremony with Suzhou Hailu Biotech, a wholly-owned subsidiary of Yangtze River Pharmaceutical Group. The collaboration will focus on deepening synergy in preclinical new drug R&D, project introduction, and global market expansion, with the goal of jointly building an efficient, open, and international R&D ecosystem spanning from source […]
Oligonucleotide Therapeutics: Conjugation Chemistry & In Vitro Activity Assessment
April 8, 2026
8:00-9:00 PM ET (5:00–6:00 PM PT)
BIO-Europe Spring 2026
March 23, 2026,
to March 25, 2026
Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche
Recently, MediLink Therapeutics entered into a new exclusive license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pharmaceutical giant, for YL201, an antibody-drug conjugate (ADC) targeting B7H3.This landmark deal, featuring an upfront payment and near-term milestone payments exceeding USD 570 million, not only serves as a strong recognition of the substantial clinical value and […]
Building a New-Drug Expressway Together, Medicilon 2025 Year-End Review
For Medicilon, 2025 was a year of steady execution and meaningful progress, strengthening our foundations, expanding our global footprint, and working closely with partners around the world to move innovative medicines forward. Throughout the year, we continued to integrate discovery, development, and regulatory readiness, connecting early scientific innovation with global clinical and regulatory pathways. Step […]
Medicilon Congratulates AI-Driven Biotech Insilico Medicine on Its HKEX Debut in Hong Kong’s Largest Biotech IPO of 2025
On December 30, Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence, successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 3696.HK). The offering raised HK$2.277 billion, making it the largest biotech IPO in Hong Kong in 2025 and the first AI-driven biotech company to list under Listing […]
Efficient Collaboration Earns High Praise: RayThera Honors Medicilon with “Excellent Partnership Award”
On November 10, Dr. Gene Hung, Founder and Chief Scientific Officer of RayThera, Inc., visited Medicilon’s Nanhui campus to further strengthen strategic collaboration and recognize outstanding achievements. During the visit, RayThera presented Medicilon with the “Excellent Partnership Award”, the Chemistry FTE Team with the “Excellent Service Team Award”, and Dr. Zhu Du, Vice President of […]
Medicilon | Featured Sponsor for ACCESS ASIA BD Forum @ JPM 2026
January 11, 2026 | InterContinental San Francisco In a world where biotech innovation thrives on collaboration, Medicilon as the Featured Sponsor for the ACCESS ASIA BD Forum @ JPM 2026. Our Mission: Your Partner from Concept to IND As a global leader in integrated preclinical research services, Medicilon has long been the bridge between discovery […]
Advancing a New Paradigm in Drug Development: Medicilon and Xellar Biosystems Forge a Strategic Partnership
Shanghai, November 6, 2025 – At the 8th China International Import Expo, Medicilon officially signed a strategic cooperation agreement with Xellar Biosystems, a biotech company pioneering the integration of organ-on-a-chip and AI technologies. This partnership combines Medicilon’s one-stop preclinical drug R&D service platform with Xellar’s advanced organ-on-a-chip systems, AI analytics, and high-content 3D imaging to […]
